Inventor · disambiguated record
Gideon Shapiro
Also filed as: SHAPIRO GIDEON
76 granted patents·45 pending applications·948 citations·filing 1988–2023
99Inventor score
Files withEPIZYME INC50ENVIVO PHARMACEUTICALS INC12FORUM PHARMACEUTICALS INC12RUGEN HOLDINGS CAYMAN LTD11RIPKA AMY5
Top patents by PatentIndex Score
121 records- 0199US9475776B2PRMT1 inhibitors and uses thereofEPIZYME INC·Filed 2015·Granted Oct 25, 2016·32 cites·9 claims
- 0299US9120757B2Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2014·Granted Sep 1, 2015·45 cites·36 claims
- 0399US9023883B2PRMT1 inhibitors and uses thereofEPIZYME INC·Filed 2014·Granted May 5, 2015·46 cites·20 claims
- 0498US9943504B2Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2016·Granted Apr 17, 2018·14 cites·17 claims
- 0598US9630961B2Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2015·Granted Apr 25, 2017·21 cites·24 claims
- 0698US9394258B2Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2014·Granted Jul 19, 2016·39 cites·13 claims
- 0798US9365527B2Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2014·Granted Jun 14, 2016·35 cites·33 claims
- 0898US9346802B2CARM1 inhibitors and uses thereofEPIZYME INC·Filed 2014·Granted May 24, 2016·38 cites·32 claims
- 0998US9133189B2Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2014·Granted Sep 15, 2015·45 cites·20 claims
- 1097US10118931B2CARM1 inhibitors and uses thereofEPIZYME INC·Filed 2017·Granted Nov 6, 2018·19 cites·4 claims
- 1197US9765035B2Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2014·Granted Sep 19, 2017·15 cites·14 claims
- 1297US9718816B21-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereofEPIZYME INC·Filed 2014·Granted Aug 1, 2017·25 cites·28 claims
- 1397US9440950B2Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2015·Granted Sep 13, 2016·34 cites·16 claims
- 1497US9045455B2Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2014·Granted Jun 2, 2015·46 cites·20 claims
- 1596US9868703B2PRMT1 inhibitors and uses thereofEPIZYME INC·Filed 2016·Granted Jan 16, 2018·15 cites·2 claims
- 1696US9856267B2CARM1 inhibitors and uses thereofEPIZYME INC·Filed 2017·Granted Jan 2, 2018·14 cites·4 claims
- 1796US9732041B2Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2016·Granted Aug 15, 2017·17 cites·9 claims
- 1896US9598374B2Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2014·Granted Mar 21, 2017·25 cites·9 claims
- 1996US9447079B2PRMT1 inhibitors and uses thereofEPIZYME INC·Filed 2014·Granted Sep 20, 2016·38 cites·13 claims
- 2096US9346761B2Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2014·Granted May 24, 2016·38 cites·36 claims
- 2196US8952026B2PRMT1 inhibitors and uses thereofEPIZYME INC·Filed 2014·Granted Feb 10, 2015·47 cites·20 claims
- 2294US9724332B2Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2015·Granted Aug 8, 2017·7 cites·29 claims
- 2394US8071595B21,2-disubstituted heterocyclic compoundsRIPKA AMY·Filed 2009·Granted Dec 6, 2011·23 cites·4 claims
- 2494US7541147B2Materials and methods for detection of nucleic acidsERAGEN BIOSCIENCES INC·Filed 2006·Granted Jun 2, 2009·21 cites·12 claims
- 2593US10294230B23,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonistsRUGEN HOLDINGS CAYMAN LTD·Filed 2018·Granted May 21, 2019·9 cites·28 claims
- 2693US10081603B2Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2017·Granted Sep 25, 2018·9 cites·27 claims
- 2793US9567341B2Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonistsRUGEN HOLDINGS (CAYMAN) LTD·Filed 2015·Granted Feb 14, 2017·12 cites·17 claims
- 2893US7422850B2Materials and methods for detection of nucleic acidsERAGEN BIOSCIENCES INC·Filed 2001·Granted Sep 9, 2008·49 cites·16 claims
- 2992US11185531B2Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2020·Granted Nov 30, 2021·2 cites·20 claims
- 3092US9776972B2Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2014·Granted Oct 3, 2017·14 cites·31 claims
- 3192US7517651B2Materials and methods for detection of nucleic acidsERAGEN BIOSCIENCES INC·Filed 2006·Granted Apr 14, 2009·15 cites·8 claims
- 3291US10227307B2PRMT1 inhibitors and uses thereofEPIZYME INC·Filed 2017·Granted Mar 12, 2019·6 cites·18 claims
- 3391US10039748B2PRMT1 inhibitors and uses thereofEPIZYME INC·Filed 2016·Granted Aug 7, 2018·9 cites·13 claims
- 3491US9968610B2Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonistsRUGEN HOLDINGS CAYMAN LTD·Filed 2017·Granted May 15, 2018·9 cites·17 claims
- 3591US9725453B2Imidazotriazinone compoundsIRONWOOD PHARMACEUTICALS INC·Filed 2014·Granted Aug 8, 2017·7 cites·2 claims
- 3690US11136328B23,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonistsRUGEN HOLDINGS CAYMAN LTD·Filed 2020·Granted Oct 5, 2021·2 cites·20 claims
- 3790US10632103B2Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2018·Granted Apr 28, 2020·3 cites·20 claims
- 3889US10030026B2Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonistsRUGEN HOLDINGS CAYMAN LTD·Filed 2015·Granted Jul 24, 2018·9 cites·20 claims
- 3987US10800743B2Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2018·Granted Oct 13, 2020·2 cites·20 claims
- 4087US8343973B2Phenoxymethyl heterocyclic compoundsENVIVO PHARMACEUTICALS INC·Filed 2009·Granted Jan 1, 2013·7 cites·4 claims
- 4186US10584127B23,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonistsRUGEN HOLDINGS CAYMAN LTD·Filed 2016·Granted Mar 10, 2020·4 cites·27 claims
- 4286US10420768B2Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonistsRUGEN HOLDINGS CAYMAN LTD·Filed 2018·Granted Sep 24, 2019·4 cites·10 claims
- 4385US10221182B23,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonistsRUGEN HOLDINGS CAYMAN LTD·Filed 2016·Granted Mar 5, 2019·5 cites·19 claims
- 4485US2024182426A1Arginine methyltransferase inhibitors and uses thereofEPIZYME INC·Filed 2023·Application pending·0 cites
- 4584US9738651B2CARM1 inhibitors and uses thereofEPIZYME INC·Filed 2014·Granted Aug 22, 2017·4 cites·18 claims
- 4684US8815933B2Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereofENVIVO PHARMACEUTICALS INC·Filed 2014·Granted Aug 26, 2014·4 cites·13 claims
- 4783US10633389B2CARM1 inhibitors and uses thereofEPIZYME INC·Filed 2018·Granted Apr 28, 2020·2 cites·18 claims
- 4883US9108961B2Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochlorideENVIVO PHARMACEUTICALS INC·Filed 2014·Granted Aug 18, 2015·5 cites·16 claims
- 4983US8614235B2CAI-based systems and methods for the localized treatment of ocular and other diseasesROBINSON GARY·Filed 2011·Granted Dec 24, 2013·8 cites·10 claims
- 5083US8217064B2Tetrasubstituted benzenesSHAPIRO GIDEON·Filed 2008·Granted Jul 10, 2012·5 cites·24 claims
Showing the top 50 of 121 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Gideon Shapiro files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →